Pioglitazone: here's the fair price
This is what US pharmacies pay, on average, for pioglitazone. Use it to spot a fair cash price, and feel good about asking for one.
Pioglitazone Hcl 15 Mg Tablet
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Pioglitazone Hcl 15 Mg Tablet. Pharmacies pay about $2.09 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| PIOGLITAZONE HCL 15 MG TABLETGeneric | $0.07 per tablet or capsule | $2.09 | 10/21/2026 |
| PIOGLITAZONE HCL 30 MG TABLETGeneric | $0.10 per tablet or capsule | $2.90 | 10/21/2026 |
| PIOGLITAZONE HCL 45 MG TABLETGeneric | $0.12 per tablet or capsule | $3.49 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . Important Limitations of Use Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see ] . Pioglitazone is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: • Congestive heart failure [see and ] • Edema [see Warnings and Precautions ] • Fractures [see Warnings and Precautions ] Most common adverse reactions (≥5%) are upper respiratory tract infection, headache, sinusitis, myalgia, and pharyngitis. To report SUSPECTED ADVERSE REACTIONS, contact Rising Health, LLC at 1-833-395-6928 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction...
Drug interactions (from the label)
7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit pioglitazone dose to 15 mg daily. , • CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. • Topiramate may decrease pioglitazone concentrations. 7.1 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t 1/2 ) of pioglitazone. Therefore, the maximum recommended dose of pioglitazone is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see and ]. 7.2 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin)...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS • Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. • Hypoglycemia: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of hypoglycemia. • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt pioglitazone and assess patient for probable cause, then treat cause if possible, to...
Source: FDA drug label via openFDA, label effective 2026-08-17. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.